{"prompt": "['Protocol RS-001', 'Confidential', 'with those who have received attenuated live vaccines should be avoided during the ABI-009', 'dosing period.', '4. Participant tests positive for Hepatitis C antibodies or the Hepatitis B antigen. HBsAg and', 'HCVAb blood test must be done at screening (HBsAg only needs to be screened in patients', 'who have not received the full complement of Hepatitis B immunizations). Alternatively, if', 'the patient has received the complement of Hepatitis B immunizations and documentation is', 'provided, this would suffice.', '5. A known history of HIV seropositivity. HIV-positive patients on combination antiretroviral', 'therapy are ineligible because of the potential for pharmacokinetic interactions with ABI-', '009. In addition, these patients are at increased risk of lethal infections when treated with', 'marrow-suppressive therapy.', '6. Participant is receiving chronic, systemic treatment with corticosteroids or another', 'immunosuppressive agent. Note: Patients that are currently using inhaled, intranasal, ocular,', 'topical or other non-oral or non-IV steroids are not necessarily excluded from the study but', 'must be discussed with the study chair.', '7. Participant has been previously treated with a systemic mTOR inhibitor for epilepsy. Skin', 'cream use with rapamycin or everolimus, however, is permitted.', '8.', 'Participant has a known hypersensitivity to human albumin, ABI-009 or other rapamycins', '(e.g. sirolimus, everolimus, temsirolimus).', '9. Participant is receiving any other concurrent anticancer or investigational therapy.', 'Participants will be permitted to enroll in the study after a 30-day washout of previously used', 'investigational drugs.', '10. Participant has any clinically significant unrelated systemic illness that would compromise a', \"participant's ability to tolerate protocol procedures.\", '11. Participant is unable to return for dosing and follow-up visits to assess toxicity to the study', 'drug.', '12. Participant has uncontrolled intercurrent illness including, but not limited to, ongoing or', 'active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac', 'arrhythmia, active lung disease, or psychiatric illness/social situations that would limit', 'compliance with study requirements. Study Specific Tolerance for Inclusion/Exclusion', 'Criteria', 'Patients who fail to meet one or more of the inclusion criteria or who meet any of the exclusion', 'criteria will not be enrolled in this study. Waivers of any of the above study entry criteria will not', 'be granted.', '7', 'CONCURRENT MEDICATIONS', 'All participants should be maintained on the same medications throughout the entire study', 'period, as medically feasible, with no introduction of new chronic therapies.', 'Version 2', 'Version Date: October 31, 2018', 'Page 39 of 72']['Protocol RS-001', 'Confidential', '7.1', 'Allowed Medications and Treatments', 'Standard therapy for epilepsy and related conditions is allowed except for treatments noted in the', 'exclusion criteria described above and as noted in the prohibited medications section below. A', 'stable therapeutic regimen between screening and Visit 1 is the goal, as well as through the', 'baseline period. Once enrolled and started into the baseline observation period, changes in AED', 'medication regimen are not permitted unless it is solely for dose adjustments secondary to sub-', 'or super-therapeutic serum levels. Participants that have been on a chronic AED regimen will be', 'mandated to continue them throughout the entire study period. Treatment for prolonged seizures', \"(>5 minutes) or clusters of seizures can be used per participant's previous rescue prescription.\", '7.2', 'Prohibited Medications and Treatments', 'Administration of immunosuppressant or chemotherapeutic drugs, IV/PO corticosteroids', 'prescribed outside the context of the investigational protocol, and attenuated live vaccines, as', 'well as any investigational drugs or biologics, is prohibited while the participant is enrolled in', 'the study.', '8', 'STUDY DRUG DOSING', '8.1', 'Method of Assigning Participants to Dosing Groups', 'Up to 18 eligible participants will be enrolled to receive the study drug (ABI-009). There will be', 'no randomization, and this will be an open-label trial. Participants will be assigned according to', 'a standard 3+3 dose escalation design, in the order that they are enrolled.', 'Participants must meet all inclusion criteria and no exclusion criteria should apply. The', 'participant must have signed and dated an approved, current version of all applicable consent', 'forms. To allow non-English speaking participants to participate in this study, bilingual health', 'services will be provided in the appropriate language when feasible.', '8.2', 'Blinding', 'This is an open label study; no blinding to dosing assignment will be performed.', '8.3', 'Formulation of Test and Control Products', '8.3.1 Formulation and Administration of Test Product', 'Refer to the Pharmacy Manual for complete information.', 'ABI-009 is provided as a lyophilized powder containing 100 mg rapamycin/vial. Each vial of', 'study drug will be labeled per standard requirements.', '8.3.2 Formulation of Control Product', 'No control product will be used in this study.', 'Version 2', 'Version Date: October 31, 2018', 'Page 40 of 72']\n\n###\n\n", "completion": "END"}